Trial Profile
A phase II, multicenter study of apatinib in progressive/recurrent glioblastoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 15 Nov 2017 New trial record